The Platelet/Monocyte Ratio Before Treatment Predicts Prognosis in Solid Childhood Cancers

Özlem Terzi (Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.)
Cengiz Bayram (Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey)
Ali Ayçiçek (Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.)
Ezgi Uysalol (Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.)
Cennet Nur Baş (Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.)
Hüseyin Avni Solgun (Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.)
Tuba Tahtakesen (Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.)
Esra Arslantaş (Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.)
Sibel Tekgündüz (Pediatric Hematology and Oncology, Basaksehir Cam and Sakura Training and Research Hospital Istanbul, Health Science University, Turkey.)

Medical Laboratory Technology Journal
Vol. 8 No. 2 (2022): December

The prognostic value of thrombocytosis and inflammatory biomarkers in adult cancer patients has been the subject of many studies. This study investigated the role of platelet count and other inflammatory biomarkers in the prognosis of solid childhood tumours. The data of 176 pediatric patients diagnosed with solid tumours were evaluated retrospectively; 150 patients still under follow-up were included in the study. We examined the relationship between platelet count, platelet/neutrophil ratio (PNR), platelet/lymphocyte ratio (PLR) and platelet/monocyte ratio (PMR) at the time of diagnosis on survival. The mean age of diagnosis was 7.91 ± 5.75 years, and 60.7% were male. The mean platelet count of the patients was 424.326 ± 167197.32. The median (range) follow-up was 13 (1-68) months. Relapse was seen in 18% of the patients, and 9.3% died. The relationship between PMR and overall survival (OS) and event-free survival times (EFS) was statistically significant (p=0.002 and p=0.016, respectively). However, no statistically significant association was found for PLR or PNR. Overall survival and EFS were significantly poorer in this cohort in patients with high pretreatment PMR.